VolitionRx Limited — FY2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012; this is an annual report, not a standalone fourth-quarter filing. Filed March 29, 2013. The company was a development-stage life sciences business developing blood-based cancer diagnostics, with no products cleared for clinical diagnostic use.
Financial results and liquidity
| Metric | FY2012 | FY2011 |
|---|---|---|
| Revenue | $54,968 | $0 |
| Operating expenses | $4,138,018 | $2,608,463 |
| Net loss | $4,083,050 | $2,608,463 |
| Basic and diluted loss per share | $0.44 | $0.45 |
| Net cash used in operations | $2,314,582 | $1,652,435 |
| Cash at year-end | $376,421 | $347,892 |
| Total liabilities | $1,382,971 | $1,156,299 |
Revenue came from HyperGenomics library-preparation services; the filing reports no meaningful gross margin. Research and development expense was approximately $2.84 million, up from $1.52 million. Operating expenses rose 59%, primarily reflecting increased R&D activity, professional fees and warrant compensation. The weighted-average share count increased 62% to 9,359,934.
At year-end, total current assets were $695,142 and current liabilities were $747,770. Management separately reported a $303,461 working-capital deficit; the filing’s description of the assets used in that calculation does not reconcile clearly to the balance-sheet totals. Current debt included a $52,860 related-party note; the balance sheet also showed a $635,201 repayable grant liability. The auditor cited accumulated losses of $7.59 million, negative operating cash flows and negative working capital, and expressed substantial doubt about the company’s ability to continue as a going concern.
Business progress and changes
- Preliminary internal testing of a NuQ assay in 105 samples reported cancer detection rates of 76% for colon, 96% for breast and 100% for lung, with reported specificity of 86%–90%. These were small-sample results, not peer-reviewed or published.
- The company reported launching NuQ research-use-only (RUO) kits in 2012, while other passages say products were not yet available for sale on the RUO market. This status is inconsistent within the filing and merits verification.
- HyperGenomics generated the company’s first service revenue. Pilot studies for the proposed endometriosis test were completed, with larger studies planned.
- There were no clinical IVD products for sale, and the company had not begun FDA or CE Mark approval applications. FY2012 equity issuance generated approximately $2.58 million in cash proceeds.
Outlook, risks and contingencies
Management expected to rely on further equity financing and said available cash was sufficient for only a limited period. A subsequent private placement generated $471,000 cash in March 2013, plus conversion of $18,583 of service obligations into shares. The company also expected approximately $600,000 in Walloon Region grant funds, but receipt was delayed and not assured. Without additional financing, research, validation and regulatory work could be delayed or operations could cease.
Management’s stated targets included NuQ CE Mark applications by late 2013 or the first half of 2014, FDA-related prospective studies beginning in 2013 and completion targeted for 2015, and potential point-of-care market entry in Europe in 2015 and the U.S. in 2016. These were forward-looking estimates, not assured milestones. The company estimated approval costs of about $500,000 per test for CE Marking and $825,000 per product for FDA approval.
Other risks include uncertain clinical performance and regulatory outcomes, competition from substantially larger companies, dependence on external financing, possible dilution, and grant repayment terms. Under the Walloon grant, at least $415,488 may be repayable if the project fails; if successful, repayment includes that minimum plus a 6% royalty on relevant sales, subject to a stated cap. The filing also disclosed material weaknesses in financial reporting controls: no audit committee financial expert, inadequate cash controls and insufficiently formalized data backup/off-site storage.
Investor verification priorities
- Confirm current cash runway, financing needs, and whether the expected Walloon grant was received and on what terms.
- Reconcile the reported working-capital deficit with balance-sheet current assets and liabilities; confirm the grant liability and repayment exposure.
- Verify whether NuQ RUO kits were actually launched and whether they generated sales, given conflicting statements in the filing.
- Seek independent, adequately powered validation of the preliminary NuQ results and track regulatory submissions and approvals against stated timelines.
- Assess dilution from subsequent equity placements, outstanding options and warrants, and the company’s remediation of disclosed control weaknesses.